Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.

Clinical breast cancer - 1 Oct 2016

Nakauchi Chiaki, Kagara Naofumi, Shimazu Kenzo, Shimomura Atsushi, Naoi Yasuto, Shimoda Masafumi, Kim Seung Jin, Noguchi Shinzaburo

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) within a liquid biopsy is a promising marker for genotyping metastatic tumors. MATERIALS AND METHODS: We performed next generation whole exon sequencing of TP53 and PIK3CA genes, which are the 2 most common genetic alterations in breast cancer, in plasma DNA (pDNA) of 17 metastatic breast cancer (MBC) patients and in tumor DNA (tDNA) from their primary tumors. RESULTS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Biopsy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to DNA, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasm Recurrence, Local

Share to Phosphatidylinositol 3-Kinases

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 27265061
DOI: 10.1016/j.clbc.2016.05.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.PMID 27265061Read ↗

Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.Semantic proximity Read ↗

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer DiagnosisSemantic proximity Read ↗

Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation SequencingSemantic proximity Read ↗

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer PatientsSemantic proximity Read ↗

PIK 3 CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison studySemantic proximity Read ↗

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.